Details of the Drug Combination

General Information of Drug Combination (ID: DCFMABY)

• Drug Combination Name: Docetaxel + Enzalutamide
• Indication: Metastatic Castration Resistant Prostate Cancer; Status: Phase 3 [1]
• Component Drugs:
  Docetaxel (DMDI269): Small molecular drug
  Enzalutamide (DMGL19D): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Docetaxel

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[2]
Breast carcinoma	N.A.	Approved	[2]
Head and neck cancer	2D42	Approved	[2]
Leiomyosarcoma	2B58	Approved	[2]
Lung cancer	2C25.0	Approved	[2]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Prostate adenocarcinoma	N.A.	Approved	[2]
Prostate cancer	2C82.0	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Urinary system neoplasm	N.A.	Approved	[2]
Gastric cancer	2B72	Investigative	[2]

Docetaxel Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[8]

Docetaxel Interacts with 8 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[9]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[10]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[13]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[14]
TAP-like protein (ABCB9)	DT68UV2	ABCB9_HUMAN	Substrate	[15]
Multidrug resistance-associated protein 7 (ABCC10)	DTPS120	MRP7_HUMAN	Substrate	[16]

Docetaxel Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[18]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Metabolism	[18]

Docetaxel Interacts with 41 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Response To Substance	[19]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)	OTBPCU2O	TR10A_HUMAN	Increases Expression	[20]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[20]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Degradation	[21]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[22]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Increases Expression	[23]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Phosphorylation	[24]
Keratin, type I cytoskeletal 18 (KRT18)	OTVLQFIP	K1C18_HUMAN	Increases Expression	[25]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[24]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[26]
Natriuretic peptides B (NPPB)	OTSN2IPY	ANFB_HUMAN	Increases Expression	[27]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Decreases Expression	[28]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[29]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[23]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[23]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Decreases Expression	[28]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Decreases Expression	[30]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Activity	[21]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Decreases Phosphorylation	[21]
ELL-associated factor 2 (EAF2)	OTSOET5L	EAF2_HUMAN	Decreases Expression	[28]
Small integral membrane protein 14 (SMIM14)	OT47IF19	SIM14_HUMAN	Decreases Expression	[28]
Protein FAM117A (FAM117A)	OT2FBGGV	F117A_HUMAN	Decreases Expression	[28]
Tumor necrosis factor receptor superfamily member 19 (TNFRSF19)	OTTVT4MB	TNR19_HUMAN	Decreases Expression	[28]
Tropomodulin-2 (TMOD2)	OTTTUH2W	TMOD2_HUMAN	Decreases Expression	[28]
Flavin-containing monooxygenase 3 (FMO3)	OT1G2EV3	FMO3_HUMAN	Affects Response To Substance	[31]
Kinesin heavy chain isoform 5A (KIF5A)	OT3ETTI6	KIF5A_HUMAN	Decreases Response To Substance	[32]
Regulator of G-protein signaling 17 (RGS17)	OT5RVUDS	RGS17_HUMAN	Increases Response To Substance	[33]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B)	OT8KME51	BUB1B_HUMAN	Affects Response To Substance	[34]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Response To Substance	[35]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Decreases Response To Substance	[36]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Increases Response To Substance	[37]
Kinesin-like protein KIFC3 (KIFC3)	OTOPD4QO	KIFC3_HUMAN	Decreases Response To Substance	[32]
Regulator of G-protein signaling 10 (RGS10)	OTQ8N1QH	RGS10_HUMAN	Increases Response To Substance	[33]
E3 ubiquitin-protein ligase CHFR (CHFR)	OTRAD2TT	CHFR_HUMAN	Decreases Response To Substance	[38]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Response To Substance	[39]
Kinesin-like protein KIF12 (KIF12)	OTTALNDD	KIF12_HUMAN	Decreases Response To Substance	[32]
Flavin-containing monooxygenase 2 (FMO2)	OTUJUL9S	FMO2_HUMAN	Affects Response To Substance	[31]
Kinesin-like protein KIF14 (KIF14)	OTXHT4JM	KIF14_HUMAN	Decreases Response To Substance	[40]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)	OTXNGZCG	MD2L1_HUMAN	Affects Response To Substance	[34]
Cellular retinoic acid-binding protein 2 (CRABP2)	OTY01V9G	RABP2_HUMAN	Affects Response To Substance	[41]
ATP-binding cassette sub-family C member 6 (ABCC6)	OTZT0LKT	MRP6_HUMAN	Affects Response To Substance	[31]

Indication(s) of Enzalutamide

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[4]

Enzalutamide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Modulator	[44]

Enzalutamide Interacts with 87 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Very long chain fatty acid elongase 7 (ELOVL7)	OT89NYVC	ELOV7_HUMAN	Decreases Expression	[42]
Bone morphogenetic protein receptor type-1B (BMPR1B)	OTGFN0OD	BMR1B_HUMAN	Decreases Expression	[42]
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2)	OTKOZRZP	PLOD2_HUMAN	Decreases Expression	[42]
RNA polymerase II elongation factor ELL2 (ELL2)	OTZJRTFM	ELL2_HUMAN	Decreases Expression	[42]
Suppressor of cytokine signaling 2 (SOCS2)	OTBPNKJQ	SOCS2_HUMAN	Decreases Expression	[42]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Decreases Expression	[42]
Unconventional myosin-Ib (MYO1B)	OTGZUJ0I	MYO1B_HUMAN	Decreases Expression	[42]
Kinesin heavy chain isoform 5C (KIF5C)	OT35570Y	KIF5C_HUMAN	Decreases Expression	[42]
Transcription factor Maf (MAF)	OT1GR3IZ	MAF_HUMAN	Decreases Expression	[42]
Solute carrier family 22 member 3 (SLC22A3)	OTQYGVXX	S22A3_HUMAN	Decreases Expression	[42]
Tyrosine-protein kinase Lck (LCK)	OT883FG9	LCK_HUMAN	Decreases Expression	[42]
Microtubule-associated protein 2 (MAP2)	OT6UYT3X	MTAP2_HUMAN	Decreases Expression	[42]
Plastin-2 (LCP1)	OTK61F2A	PLSL_HUMAN	Decreases Expression	[42]
Kallikrein-2 (KLK2)	OT9RE37R	KLK2_HUMAN	Decreases Expression	[42]
Phospholipase A2 group V (PLA2G5)	OTQRSKCZ	PA2G5_HUMAN	Decreases Expression	[42]
Regulator of G-protein signaling 2 (RGS2)	OT0FSRW7	RGS2_HUMAN	Decreases Expression	[42]
Retinaldehyde dehydrogenase 3 (ALDH1A3)	OT1C9NKQ	AL1A3_HUMAN	Decreases Expression	[42]
Selenoprotein P (SELENOP)	OT02B8IR	SEPP1_HUMAN	Decreases Expression	[42]
AF4/FMR2 family member 3 (AFF3)	OTR0705Z	AFF3_HUMAN	Decreases Expression	[42]
Cysteine-rich secretory protein 3 (CRISP3)	OTBSWMPL	CRIS3_HUMAN	Decreases Expression	[42]
Tumor protein D52 (TPD52)	OTPKSK43	TPD52_HUMAN	Decreases Expression	[42]
Acyl-coenzyme A synthetase ACSM1, mitochondrial (ACSM1)	OT1TS9M9	ACSM1_HUMAN	Decreases Expression	[42]
Ras GTPase-activating-like protein IQGAP2 (IQGAP2)	OTX2UA7P	IQGA2_HUMAN	Decreases Expression	[42]
Glycine N-methyltransferase (GNMT)	OT0O2OQO	GNMT_HUMAN	Decreases Expression	[42]
Ketimine reductase mu-crystallin (CRYM)	OTRGSR6B	CRYM_HUMAN	Decreases Expression	[42]
Manganese-dependent ADP-ribose/CDP-alcohol diphosphatase (ADPRM)	OTXE3X5J	ADPRM_HUMAN	Decreases Expression	[42]
Protein GREB1 (GREB1)	OTU6ZA26	GREB1_HUMAN	Decreases Expression	[42]
EF-hand calcium-binding domain-containing protein 12 (EFCAB12)	OT1QZJEI	EFC12_HUMAN	Decreases Expression	[42]
Rho-related GTP-binding protein RhoU (RHOU)	OTERIAD4	RHOU_HUMAN	Decreases Expression	[42]
Transient receptor potential cation channel subfamily M member 8 (TRPM8)	OT7ACGYK	TRPM8_HUMAN	Decreases Expression	[42]
Alpha-protein kinase 2 (ALPK2)	OTWZZDQ9	ALPK2_HUMAN	Decreases Expression	[42]
Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial (AADAT)	OTO68C3Y	AADAT_HUMAN	Decreases Expression	[42]
Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1)	OTBML9D9	CGAT1_HUMAN	Decreases Expression	[42]
Specifically androgen-regulated gene protein (C1ORF116)	OTPYEXDM	SARG_HUMAN	Decreases Expression	[42]
ER degradation-enhancing alpha-mannosidase-like protein 3 (EDEM3)	OT4GJX9R	EDEM3_HUMAN	Decreases Expression	[42]
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (ST6GALNAC1)	OT3JQD99	SIA7A_HUMAN	Decreases Expression	[42]
Teneurin-1 (TENM1)	OTSKSU4V	TEN1_HUMAN	Decreases Expression	[42]
Transmembrane and coiled-coil domain protein 3 (TMCC3)	OTAIQ6V6	TMCC3_HUMAN	Decreases Expression	[42]
E3 ubiquitin-protein ligase NEURL1B (NEURL1B)	OT3BZWO8	NEU1B_HUMAN	Affects Expression	[43]
Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)	OTOKUXUH	ADA10_HUMAN	Affects Expression	[43]
Integrin beta-1-binding protein 1 (ITGB1BP1)	OTVQFNGS	ITBP1_HUMAN	Affects Expression	[43]
Sushi domain-containing protein 5 (SUSD5)	OTIMJGDH	SUSD5_HUMAN	Affects Expression	[43]
Polycomb protein EED (EED)	OTJFHCDF	EED_HUMAN	Decreases Expression	[45]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[46]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Affects Expression	[43]
Annexin A4 (ANXA4)	OTUCRYXL	ANXA4_HUMAN	Affects Expression	[43]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Decreases Cleavage	[46]
Midkine (MDK)	OTF24HKC	MK_HUMAN	Affects Expression	[43]
Hepatocyte nuclear factor 1-beta (HNF1B)	OTSYIC3T	HNF1B_HUMAN	Affects Expression	[43]
Small ribosomal subunit protein eS19 (RPS19)	OTBKGP48	RS19_HUMAN	Affects Expression	[43]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Affects Expression	[43]
Neurogenic locus notch homolog protein 1 (NOTCH1)	OTI1WADQ	NOTC1_HUMAN	Affects Expression	[43]
Transcription factor SOX-9 (SOX9)	OTVDJFGN	SOX9_HUMAN	Affects Expression	[43]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Affects Expression	[43]
Hepatocyte nuclear factor 3-alpha (FOXA1)	OTEBY0TD	FOXA1_HUMAN	Affects Expression	[43]
Ubiquitin-ribosomal protein eS31 fusion protein (RPS27A)	OTIIGGZ2	RS27A_HUMAN	Affects Expression	[43]
Protein jagged-1 (JAG1)	OT3LGT6K	JAG1_HUMAN	Affects Expression	[43]
Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17)	OTTM6KRB	ADA17_HUMAN	Affects Expression	[43]
Neurogenic locus notch homolog protein 2 (NOTCH2)	OTQ3Y9PA	NOTC2_HUMAN	Affects Expression	[43]
Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP5)	OT404F9K	FKBP5_HUMAN	Decreases Expression	[46]
SNW domain-containing protein 1 (SNW1)	OTKWG3PS	SNW1_HUMAN	Affects Expression	[43]
Transcription factor HES-1 (HES1)	OT8P19W2	HES1_HUMAN	Affects Expression	[43]
Polycomb protein SUZ12 (SUZ12)	OT655XF8	SUZ12_HUMAN	Decreases Expression	[45]
Probable E3 ubiquitin-protein ligase DTX2 (DTX2)	OT7QLDU4	DTX2_HUMAN	Affects Expression	[43]
E3 ubiquitin-protein ligase MIB1 (MIB1)	OT5C404P	MIB1_HUMAN	Affects Expression	[43]
NF-kappa-B-activating protein (NKAP)	OT7K7I8Q	NKAP_HUMAN	Affects Expression	[43]
Probable E3 ubiquitin-protein ligase DTX3 (DTX3)	OTSUUV9N	DTX3_HUMAN	Affects Expression	[43]
Polypeptide N-acetylgalactosaminyltransferase 11 (GALNT11)	OTANT9E6	GLT11_HUMAN	Affects Expression	[43]
Gamma-secretase subunit APH-1B (APH1B)	OTQHPTGC	APH1B_HUMAN	Affects Expression	[43]
Nicastrin (NCSTN)	OT5QBTA4	NICA_HUMAN	Affects Expression	[43]
Mastermind-like protein 1 (MAML1)	OTQA4DDN	MAML1_HUMAN	Affects Expression	[43]
E3 ubiquitin-protein ligase MIB2 (MIB2)	OTJCC3HS	MIB2_HUMAN	Affects Expression	[43]
p53 apoptosis effector related to PMP-22 (PERP)	OTP0YL53	PERP_HUMAN	Affects Expression	[43]
E3 ubiquitin-protein ligase Itchy homolog (ITCH)	OTUOMKF5	ITCH_HUMAN	Affects Expression	[43]
Mastermind-like protein 3 (MAML3)	OTZFV53Z	MAML3_HUMAN	Affects Expression	[43]
Intraflagellar transport protein 74 homolog (IFT74)	OTZBFEDD	IFT74_HUMAN	Affects Expression	[43]
RNA-binding protein 15 (RBM15)	OT8ZPGWF	RBM15_HUMAN	Affects Expression	[43]
Msx2-interacting protein (SPEN)	OT37A2MD	MINT_HUMAN	Affects Expression	[43]
GDP-fucose protein O-fucosyltransferase 1 (POFUT1)	OTOBJZIT	OFUT1_HUMAN	Affects Expression	[43]
Notchless protein homolog 1 (NLE1)	OT1BV82K	NLE1_HUMAN	Affects Expression	[43]
Gamma-secretase subunit PEN-2 (PSENEN)	OTJ7M7G9	PEN2_HUMAN	Affects Expression	[43]
Protein sel-1 homolog 1 (SEL1L)	OTC0FB7T	SE1L1_HUMAN	Affects Expression	[43]
Intraflagellar transport protein 172 homolog (IFT172)	OT12DW08	IF172_HUMAN	Affects Expression	[43]
Neurogenic locus notch homolog protein 3 (NOTCH3)	OTMVVA7F	NOTC3_HUMAN	Affects Expression	[43]
Protein jagged-2 (JAG2)	OTH7KRRF	JAG2_HUMAN	Affects Expression	[43]
E3 ubiquitin-protein ligase DTX4 (DTX4)	OTGX30AO	DTX4_HUMAN	Affects Expression	[43]
Epsin-1 (EPN1)	OT4Q1NIV	EPN1_HUMAN	Affects Expression	[43]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Metastatic Castration-Resistant Prostate Cancer (mCRPC)	DCMSCEH	N. A.	Phase 2	[47]
Metastatic Castration Resistant Prostate Cancer	DCJ5U1O	N. A.	Phase 1	[48]

References

• [1] ClinicalTrials.gov (NCT02288247) A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
• [2] Docetaxel FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
• [4] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [5] Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006 Aug 15;119(4):783-91.
• [6] Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. Int J Cancer. 2006 Jan 15;118(2):317-25. doi: 10.1002/ijc.21372.
• [7] Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer. 2005 Jun 20;115(3):484-92. doi: 10.1002/ijc.20878.
• [8] Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
• [9] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [10] Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
• [11] Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
• [12] Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
• [13] FDA Drug Development and Drug Interactions
• [14] Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
• [15] RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
• [16] Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
• [17] Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
• [18] Drug Interactions Flockhart Table
• [19] Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
• [20] Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
• [21] Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 2007 Feb 15;13(4):1308-14. doi: 10.1158/1078-0432.CCR-06-2216.
• [22] PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
• [23] Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci. 2005 Sep 1;10:2566-75. doi: 10.2741/1720.
• [24] All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene. 2004 Jan 15;23(2):426-33. doi: 10.1038/sj.onc.1207040.
• [25] Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
• [26] Replication-dependent -H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells. Oncol Rep. 2010 Nov;24(5):1297-305. doi: 10.3892/or_00000986.
• [27] Docetaxel induced cardiotoxicity. Heart. 2001 Aug;86(2):219. doi: 10.1136/heart.86.2.219.
• [28] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [29] [The mechanism of docetaxel-induced apoptosis in human lung cancer cells]. Zhonghua Zhong Liu Za Zhi. 2000 May;22(3):208-11.
• [30] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [31] Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
• [32] Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.
• [33] Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer. 2010 Nov 2;9:289. doi: 10.1186/1476-4598-9-289.
• [34] Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
• [35] [Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere]. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8.
• [36] Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
• [37] HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat. 2004 Aug;86(3):197-206. doi: 10.1023/B:BREA.0000036783.88387.47.
• [38] Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
• [39] Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
• [40] KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia. 2014 Mar;16(3):247-56, 256.e2. doi: 10.1016/j.neo.2014.03.008.
• [41] The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. Chem Biol Interact. 2023 Mar 1;373:110372. doi: 10.1016/j.cbi.2023.110372. Epub 2023 Feb 2.
• [42] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [43] NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
• [44] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [45] Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer. Toxicol Appl Pharmacol. 2020 Oct 1;404:115200. doi: 10.1016/j.taap.2020.115200. Epub 2020 Aug 14.
• [46] Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance. J Biol Chem. 2020 Apr 17;295(16):5470-5483. doi: 10.1074/jbc.RA119.011385. Epub 2020 Mar 17.
• [47] ClinicalTrials.gov (NCT04015622) PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
• [48] ClinicalTrials.gov (NCT03328364) A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden